Csquare’s rebound has a bookings story, but the IPO gap remains
CSQR’s supplied chart shows $17.52 and +14.73%. Stronger bookings and guidance add context, while losses and the IPO-price gap remain important.
Read the story
CSQR’s supplied chart shows $17.52 and +14.73%. Stronger bookings and guidance add context, while losses and the IPO-price gap remain important.
Read the story
IPOsCsquare, Iambic and Micware feature in a supplied gainers screen. November 9–10 earnings and analyst coverage offer context, with important caveats.

FutureFuel’s stronger sales and narrower loss are encouraging, but cash outflow clouds the recovery. Its next-quarter forecast now needs proof.

iHeartMedia sharply reduced its 2026 profit and cash-flow outlook. Radio advertising weakness and heavy debt help explain concerns behind the IHRT selloff.

Microvast’s sharp snapshot decline follows weaker sales, shrinking margins and an unresolved going-concern warning. Debt refinancing is now a central risk.

MIND CTI’s snapshot rally brings shares close to Enghouse’s proposed cash price. Approval, closing risk and the remaining merger spread now matter.

SMX’s new AI materials announcement adds to its sharp rally. The project remains in development, while a recent reverse split complicates historical comparisons.

PepGen’s sharp snapshot gain accompanies new DM1 trial data. Small patient numbers, an active U.S. clinical hold and future funding remain important.

SMX and Wellchange appear with strong gains in the supplied Penny Gems snapshot, but November 9 reverse splits make comparable prices and share counts essential context.

Netcapital has until February 9 to file overdue reports. The snapshot rally brings attention, while missing financial statements and separate SEC allegations remain key context.

The latest supplied CODX snapshot shows $0.45 and a 74.45% gain. India tuberculosis plans, November 10 earnings and convertible financing frame the business story.

Heron’s proposed asset sale brings cash and CorMedix shares, but closing conditions, debt and its next business strategy remain central for HRTX holders.